TRIPLE NEGATIVE BREAST CANCER

This early-stage study tested a new drug called HMBD-002, alone or with another drug (pembrolizumab), in 48 adults with advanced solid tumors (like lung or breast cancer) that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, …

This study tested a new drug (TJ004309) combined with an approved immunotherapy (atezolizumab) in 25 people with advanced ovarian, head and neck, lung, gastrointestinal, or triple-negative breast cancers. The goal was to see if the combination could shrink tumors. Participants ha…

This study tested a specific chemotherapy combination given before surgery in 29 people with triple-negative breast cancer, a fast-growing type. The goal was to see if the treatment could completely clear all cancer from the breast and nearby lymph nodes. Researchers measured how…

This study tested a combination of two drugs, lenvatinib and pembrolizumab, in 611 people with advanced solid tumors including breast, ovarian, stomach, colorectal, brain, bile duct, and pancreatic cancers that had stopped responding to standard treatments. The goal was to see if…

This study tested whether adding the immunotherapy drug toripalimab to standard chemotherapy (nab-paclitaxel) helps people with advanced triple-negative breast cancer live longer without their cancer growing. About 531 participants with metastatic or recurrent disease were enroll…

This study tested a combination of two drugs, NT-I7 and pembrolizumab, in 215 people with advanced solid tumors that had come back or stopped responding to treatment. The goal was to find a safe dose and see if the combo could shrink tumors. The study included people with several…

This study tested a combination of two drugs, crizotinib (a tablet) and fulvestrant (an injection), in 33 people with advanced lobular breast cancer that is estrogen-receptor positive. It also tested crizotinib alone in people with diffuse gastric cancer, triple-negative lobular …

This study tested a combination of two drugs (sintilimab and anlotinib) plus standard chemotherapy given before surgery to people with early-stage triple-negative breast cancer. The goal was to see if this approach could eliminate all signs of cancer by the time of surgery. 29 pa…

This study tested the safety of combining the immunotherapy drug atezolizumab with the chemotherapy nab-paclitaxel in 184 people with advanced triple-negative breast cancer that had a specific protein (PD-L1). Participants had not received chemotherapy for their advanced disease.…

This study tested a new radioactive tracer called 89Zr-TLX250 that attaches to a protein found on some triple negative breast cancer cells. 12 people with advanced cancer received a PET scan using this new tracer, and doctors compared it to a standard PET scan to see which one fo…

This early-phase study tested an experimental immune therapy called IRX-2 in 16 people with early-stage breast cancer, including triple-negative breast cancer. The goal was to see if giving IRX-2 before standard chemotherapy is safe and whether it boosts the immune system's attac…

This study tested whether adding two supportive drugs (loperamide for diarrhea and G-CSF for low white blood cells) could reduce severe side effects of the cancer drug sacituzumab govitecan. It involved 50 adults with advanced triple-negative or luminal breast cancer that had spr…

This study looked at whether the types of bacteria in the gut and inside tumors can affect how well chemotherapy works in people with triple negative breast cancer. Researchers collected samples from 49 patients before and during standard chemotherapy to see if certain bacteria w…

This study looked at 65 people with advanced HER2-negative breast cancer who have certain gene mutations. Researchers used a test called RAD51-foci to see if it could predict how well the drug olaparib would work. The goal was to find a better way to match patients with the right…

This study looked at 147 people with triple negative breast cancer to see if a genetic test called HRD could predict which chemotherapy—cisplatin or paclitaxel—works better before surgery. Participants received one of the two drugs, and researchers measured tumor response. The go…

This study looked at whether having a breast MRI before surgery helps women with early-stage breast cancer get better surgical results. About 317 women with certain types of breast cancer took part. The goal was to see if the MRI could reduce the need for repeat surgeries and imp…

This study aimed to create a communication tool to help doctors and patients talk about cancer that stops responding to treatment. Researchers interviewed 128 people, including patients with certain breast cancers, metastatic uveal melanoma, and parents of children with cancer, a…